Join the Fiasp group to help and get support from people like you.
Fiasp News
FDA Medwatch Alert: Novo Nordisk Issues Voluntary Nationwide Recall of Levemir, Tresiba, Fiasp, Novolog and Xultophy Product Samples Due to Improper Storage Temperature Conditions
May 10, 2021 – Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level. These products are b...
FDA Approves Fiasp (insulin aspart injection) for the Treatment of Children with Diabetes
PLAINSBORO, N.J., Jan. 6, 2020 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new...
FDA Approves Fiasp (insulin aspart injection) for Use in Insulin Infusion Pumps for Adults with Type 1 or Type 2 Diabetes
PLAINSBORO, N.J., Oct. 22, 2019 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp (insulin aspart injection) 100 u/mL to...
FDA Medwatch Alert: Caution When Using Pen Needles to Inject Medicines: FDA Safety Communication
Audience: Patients and caregivers who use or are considering using pen injectors with pen needles to inject prescription medicines. Health care providers who treat patients, or who train...
Novo Nordisk Receives FDA Approval for Fiasp (insulin aspart injection), a New Fast-Acting Mealtime Insulin
PLAINSBORO, N.J., Sept. 29, 2017 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp (insulin aspart injection) 100 Units/mL, a fast-acting...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Diabetes, Type 2, Diabetes, Type 1